Burgdorf – Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon Pen, based on Ypsomed's LyoTwist® platform.
Read more... Ypsomed newly supplies AstraZeneca with the Bydureon Pen
